Novel small molecule that inhibits PAI-1 in development to slow vascular aging
An investigational inhibitor of plasminogen activator inhibitor type 1 (PAI-1) prevented arteriosclerosis in mice and prolonged life in mice with a rapid aging phenotype. As elevated PAI-1 may play a role in intravascular thrombosis, and since it is a marker of cellular senescence, the inhibitor is being developed to treat or slow down vascular aging. Phase 2 studies are being planned after phase I studies showed no sign of apparent toxicity.
Educational information
Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA
Disclosures
Douglas E. Vaughan, MD - Chair of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Share this page with your colleagues and friends: